On June 5, Tempus AI fell 5.34% in regular trading, trading at $48.535/share, with trading volume of $119 million. The decline was driven by continued heavy selling from major shareholder LEFKOFSKY ERIC P, who holds over 10% of the company, combined with broad weakness across the Life Sciences Tools & Services sector.

The major shareholder's persistent and intensive share disposals have notably weighed on market sentiment in recent sessions. Concurrently, the broader sector saw widespread declines, with Illumina down 3.18%, Agilent down 1.57%, Thermo Fisher Scientific down 1.51%, and Danaher down 0.78%, further amplifying selling pressure on Tempus AI.

Prior to this pullback, Tempus AI had rallied significantly after its xT CDx next-generation sequencing platform received FDA approval for tumor-only comprehensive genomic profiling, making it the first lab with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The company expects the approval to deliver an estimated $200 increase in average selling price starting in 2027. The current decline is viewed as continued profit-taking and technical correction following that sharp advance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)